Literature DB >> 9782241

Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery.

Y L Lim1, W Leem, T S Kim, B A Rhee, G K Kim.   

Abstract

To determine the tumor control rates and endocrinological responses after stereotactic radiosurgery for pituitary adenomas, we reviewed our experience in 65 patients (40 men, 25 women) treated in the Gamma Knife during the last 4 years. The mean age was 41.6 years (range 19-69 years). 43 patients had endocrinologically active tumors (20 growth hormone-secreting, 19 prolactin-secreting and 4 ACTH-secreting adenomas). 22 had nonfunctioning adenomas. 39 patients had a macroadenoma and 26 patients had a microadenoma. 33 patients underwent Gamma Knife radiosurgery for recurrent or residual tumors after microsurgery. 50 patients have had follow-up neuroimaging studies and/or hormonal evaluation. The follow-up period was 25.5 months (range 3 to 54 months). The margin of the tumor was incorporated within the 50 to 90% isodose. The mean number of isocenters was 3.8 and the mean marginal dose was 25.4 Gy (range 15 to 36 Gy). 27 out of 40 patients (65.7%) showed decreased tumor volume to less than 50% of the initial volume. In 17 out of 38 patients (44.7%) with endocrinologically active tumors, the hormonal level fell to within the normal range. Two patients had delayed complications: in one case there was pituitary insufficiency and in the other a visual disturbance. Gamma Knife radiosurgery seems to be effective adjuvant therapy for pituitary adenoma in selected cases. More long-term follow-up is required to evaluate the efficacy and side effects further.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9782241     DOI: 10.1159/000056412

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  19 in total

Review 1.  Radiotherapy and radiosurgery in acromegaly.

Authors:  Frédéric Castinetti; Isabelle Morange; Henry Dufour; Jean Regis; Thierry Brue
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 3.  Radiotherapy for prolactin-secreting pituitary tumors.

Authors:  Lawrence J Sheplan Olsen; Lizbeth Robles Irizarry; Samuel T Chao; Robert J Weil; Amir H Hamrahian; Betul Hatipoglu; John H Suh
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

4.  Isolated familial somatotropinoma.

Authors:  Beatriz Santana Soares; Lawrence A Frohman
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 5.  Stereotactic radiosurgery for WHO grade I meningiomas.

Authors:  Jason P Sheehan; Brian J Williams; Chun Po Yen
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

Review 6.  Pharmacotherapy or surgery as primary treatment for acromegaly?

Authors:  D Ferone; A Colao; A J van der Lely; S W Lamberts
Journal:  Drugs Aging       Date:  2000-08       Impact factor: 3.923

Review 7.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 8.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

Review 9.  Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife.

Authors:  Jay Jagannathan; Chun-Po Yen; Nader Pouratian; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

10.  Clinical and Radiologic Outcome of Gamma Knife Radiosurgery on Nonfunctioning Pituitary Adenomas.

Authors:  Shyamal C Bir; Richard D Murray; Sudheer Ambekar; Papireddy Bollam; Anil Nanda
Journal:  J Neurol Surg B Skull Base       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.